Lack of Randomized Controlled Trials (RCTs) Data

Much of the hesitance can be attributed to the absence of robust data. RCTs, which are crucial for establishing vaccine efficacy and safety, often have strict eligibility criteria, excluding immunocompromised individuals, including cancer patients. For instance, the pivotal RCT for Pfizer's mRNA vaccine did not include patients with weakened immune systems. Similarly, trials for other Covid-19 vaccines predominantly enrolled healthy participants.

A 2022 meta-review of 18 systematic reviews acknowledged this gap, stating that data on Covid-19 vaccine safety in cancer patients is limited due to the exclusion of vulnerable groups from clinical trials. However, several observational studies have attempted to bridge this gap by providing safety data.

It’s important to note that while observational studies can offer insights, they typically lack randomization, which can introduce confounding variables. For example, individuals who are ill may delay vaccination until they feel better, which can skew outcomes favorably for vaccinated groups.

Nonetheless, some observational data is still better than none.

Available Safety Data for Initial Doses

The previously mentioned meta-review indicated that only six out of the 18 systematic studies assessed vaccine safety in cancer patients, and no significant safety issues were identified. Common side effects such as pain at the injection site, muscle pain, and fatigue were reported, similar to reactions seen in the general population.

Among the few studies highlighting safety concerns, a cohort study by Oosting et al. in late 2021 followed 791 participants, including 551 with cancer. This study is notable for being one of the largest longitudinal investigations into vaccine safety among cancer patients. All participants received two doses of Moderna's mRNA vaccine.

Oosting et al. found that 16 unexpected serious adverse events (2.9% of cancer patients) occurred in those vaccinated. Of these, 10 were classified as grade 3–4 severity, which can severely impact daily activities and require hospitalization. Notably, no serious adverse events were reported in the control group.

The study documented various serious events, including urinary tract infections and sepsis, with four of the serious events potentially linked to vaccination.

In essence, serious adverse events potentially related to vaccination occurred in only 0.7% of cancer patients, which is a marginal increase compared to the control group.

Rare adverse events, such as thromboembolism, were also documented, but data for the control group was not available, leaving a gap in understanding whether these rates were elevated among cancer patients.

At the conclusion of the study, 10 cancer patients passed away due to various causes unrelated to the vaccine, including cancer progression. Oosting et al. noted that the adverse events observed aligned with known vaccine reactions and the side effects of chemotherapy and immunotherapy.

Safety Data for Booster Doses

Currently, no systematic review exists regarding the safety of booster doses for cancer patients. An informal search yielded seven relevant studies, indicating that no unexpected serious adverse events were reported among these studies; any serious events were part of the expected side effects of vaccination.

However, there are limitations to this data:

1. None of the studies were extensive, like Oosting et al.'s study.
2. Only one study assessed patients with liquid cancers.
3. The safety profile of fourth doses remains unexplored.

Despite these caveats, it is generally advised that immunocompromised individuals receive additional doses to enhance immunity. The question remains whether there is a safe limit to the number of vaccine doses a person can receive, a topic that the WHO continues to examine without definitive conclusions.

Concerns About Cancer Progression

Returning to Oosting et al.'s findings, the eight reported cases of cancer progression raise important questions. Although these cases were not deemed vaccine-related, the lack of additional data leaves room for speculation.

Several reports have surfaced detailing similar instances of cancer progression shortly after vaccination. For example, a case study detailed an 80-year-old woman who developed a mass after her first vaccine dose, which was later diagnosed as lymphoma. Another report involved a 66-year-old man whose lymphoma spread after receiving his third dose.

These cases suggest potential unknown interactions between vaccination and cancer cells, especially in lymphoma patients.

Haley Broocks, a speech-language pathologist, shared her experience with her mother, who faced complications after receiving her fifth vaccine dose and subsequently passed away. These accounts highlight the complexities surrounding vaccination and cancer progression, particularly in lymphoma cases.

Despite the existing concerns, the prevailing evidence does not support a widespread risk of vaccines exacerbating cancer progression. The rarity of such occurrences in studies suggests that while these concerns should not be dismissed, they remain statistically insignificant.

Risks and Responses: COVID 19 Vaccines and Blood Cancer Patients

This video explores the safety of Covid-19 vaccines specifically for cancer patients and the potential risks involved.

Study: COVID Vaccines Safe For Cancer Patients Receiving Chemotherapy, Radiation, Immunotherapy

This video discusses findings from studies evaluating the safety of Covid-19 vaccines in cancer patients undergoing various treatments.

In conclusion, while concerns regarding vaccine safety and cancer progression are valid, current evidence indicates that such issues are rare. Continuous investigation and transparency are crucial to address these concerns effectively.

If you found this article helpful, consider subscribing to my Medium email list or supporting my work directly.